Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Abstract Background The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. Methods Using the National Cancer Database, we identified 4725 patients aged ≥20 diagnosed...
Main Authors: | Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri, Quoc-Dien Trinh |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0782-y |
Similar Items
-
BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
by: Karam Khaddour, et al.
Published: (2021-06-01) -
IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2016-12-01) -
Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01) -
Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
by: Paul T. Finger, et al.
Published: (2019-03-01) -
Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
by: S. Morteza Seyed Jafari, et al.
Published: (2020-10-01)